Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor ZN-c3 in Subjects With Acute Myeloid Leukemia

NCT05682170 is registered in ClinicalTrials.gov with K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05682170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05682170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor ZN-c3 in Subjects With Acute Myeloid Leukemia
Lead sponsor
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 1, 2022
Completion date
July 26, 2024
Enrollment
40 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)